Bladder cancer specific ligand peptides

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10335365
APP PUB NO 20170173174A1
SERIAL NO

15400987

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO: 1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • THE REGENTS OT THE UNIVERSHY OF CALIFORNIA; THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS (WASHINGTON DC)

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Aina, Olulanu H Elk Grove, US 3 7
Lam, Kit S Davis, US 58 752
Pan, Chong-Xian Davis, US 13 17
Zhang, Hongyong Davis, US 462 30439

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 2, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 2, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00